Source: BioPharma-Reporter

REMICADE: Epirus hands Remicade biosimilar rights to Reliance Life Sciences

Epirus Biopharmaceuticals has handed rights to its Remicade (infliximab) biosimilar to Reliance Life Sciences (RLS).

Read full article »
REMICADE's Competitors | REMICADE's News | REMICADE's Financials
Stay up-to-date with the latest news on REMICADE
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on REMICADE